Federal Register / Vol. 69, No. 243 / Monday, December 20, 2004 / Notices 75995

Agenda: This portion of the meeting will 

be open to the public for announcements and 

reports of administrative, legislative and 

program developments in the drug abuse 

field. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Contact Person: Teresa Levitin, PhD, 

Director, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

443–2755. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Information is also available on the 

Institute’s/Center’s home page: http://

www.drugabuse.gov.NACDA/

NACDAHome.html, where an agenda and 

any additional information for the meeting 

will be posted when available.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research 

Scientists Awards; 93.278, Drug Abuse 

National Research Service Awards for 

Research Training; 93.279, Drug Abuse 

Research Programs, National Institutes of 

Health, HHS.)

Dated: December 13, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–27784 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The portions of the meeting devoted 

to the review and evaluation of journals 

for potential indexing by the National 

Library of Medicine will be closed to the 

public in accordance with the 

provisions set forth in section 

552b(c)(9)(B), Title 5 U.S.C., as 

amended. Premature disclosure of the 

titles of the journals as potential titles to 

be indexed by the National Library of 

Medicine, the discussions, and the 

presence of individuals associated with 

these publications could significantly 

frustrate the review and evaluation of 

individual journals.

Name of Committee: Literature Selection 

Technical Review Committee. 

Date: February 10–11, 2005. 

Open: February 10, 2005, 9 a.m. to 11 a.m. 

Agenda: Administrative reports and 

program discussions. 

Place: National Library of Medicine, 

Building 38, Board Room, 2nd Floor, 8600 

Rockville Pike, Bethesda, MD 20894. 

Closed: February 10, 2005, 11 a.m. to 5 

p.m. 

Agenda: To review and evaluate journals 

as potential titles to be indexed by the 

National Library of Medicine. 

Place: National Library of Medicine, 

Building 38, Board Room, 2nd Floor, 8600 

Rockville Pike, Bethesda, MD 20894. 

Closed: February 11, 2005, 8:30 a.m. to 2 

p.m. 

Agenda: To review and evaluate journals 

as potential titles to be indexed by the 

National Library of Medicine. 

Place: National Library of Medicine, 

Building 38, Board Room, 2nd Floor, 8600 

Rockville Pike, Bethesda, MD 20894. 

Contact Person: Sheldon Kotzin, MLS, 

Chief, Bibliographic Services Division, 

Division of Library Operations, National 

Library of Medicine, 8600 Rockville Pike, 

Bldg 38A/Room 4N419, Bethesda, MD 20894. 

Any interested person may file written 

comments with the Committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and, when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

into the building by non-government 

employees. Persons without a government 

I.D. will need to show a photo I.D. and sign 

in at the security desk upon entering the 

building.

(Catalogue of Federal Domestic Assistance 

Program No. 93.879, Medical Library 

Assistance, National Institutes of Health, 

HHS)

Dated: December 13, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy, NIH.

[FR Doc. 04–27785 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel 

Neurotechnology and Brain Imaging. 

Date: December 20, 2004. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Peter B. Guthrie, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4142, 

MSC 7850, Bethesda, MD 20892, (301) 435–

1239, guthriep@csr.nih.gov.

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Drug Use 

reduction. 

Date: December 20, 2004. 

Time: 3:30 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone conference Call). 

Contact Person: Gayle M. Boyd, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3028–D, 

MSC 7759, Bethesda, MD 20892, (301) 451–

9956, gboyd@mail.nih.gov.

This notice is being published less than 15 

days prior to the meeting due to the timing 

75996 Federal Register / Vol. 69, No. 243 / Monday, December 20, 2004 / Notices 

limitations imposed by the review and 

funding cycle.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel 

Neurogenesis/Neuronal Development. 

Date: December 21, 2004. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Carl D. Banner, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4138, 

MSC 7850, Bethesda, MD 20892, (301) 435–

1251, bannerc@csr.nih.gov.

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS)

Dated: December 10, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–27722 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review, Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4), and 552b(c)(6), Title 5 

U.S.C., as amended. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel CommunityBased Colorectal Cancer Screening. 

Date: December 20, 2004. 

Time: 11:15 a.m. to 12:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Michael Micklin, PhD, 

Chief, RPHB IRG, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 3136, MSC 7759, 

Bethesda, MD 20892, (301) 435–1258. 

micklinm@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel End of Life 

Transitions. 

Date: January 3, 2005. 

Time: 11 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge drive,Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Michael Micklin, PhD, 

Chief, RPHB IRG, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 3136, MSC 7759, 

Bethesda, MD 20892, (301) 435–1258. 

micklinm@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS.)

Dated: December 14, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–27778 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: 4′ and 4′,4′′-substituted-3-α-

(diphenylmethoxy) Tropane Analogs 

as Cocaine Therapeutics

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

license worldwide to practice the 

invention embodied in of U.S. Patent 

5,792,775, issued on August 11, 1998, 

entitled, ‘‘4′ and 4′,4′′-substituted-3-a-

(diphenylmethoxy) tropane analogs as 

cocaine therapeutics’ to Phase2 

Discovery, having a place of business in 

the state of Ohio. The field of use may 

be limited to the treatment of Attention 

Deficit Hyperactivity Disorder (ADHD). 

The United States of America is the 

assignee of the patent rights in this 

invention. This announcement is the 

first notice to grant an exclusive license 

to this technology.

DATES: Only written comments and/or 

application for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

February 18, 2005, will be considered.

ADDRESSES: Requests for a copy of the 

patent applications, inquiries, 

comments and other materials relating 

to the contemplated license should be 

directed to: Pradeep Ghosh, J.D., Ph.D., 

M.B.A., Technology Licensing 

Specialist, Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–5282; Facsimile: (301) 402–

0220; e-mail: ghoshpr@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This 

technology relates to a family of tropane 

analogs that bind to dopamine 

transporters and can be used to image 

dopamine transporter binding sites, and 

to diagnose and/or monitor 

neurodegenerative disorders and 

developmental disabilities like ADHD. 

ADHD is a neurobiological-based 

developmental disability characterized 

by inattentiveness, impulsivity, and 

hyperactivity. 

The prospective exclusive license will 

be royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552.

Dated: December 13, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–27781 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–P